A mitochondrial peptide of 16 amino acids that supports cellular energy, metabolism, physical endurance and a healthy lifestyle.
8,827 UAH
Orders are processed and handed over for delivery within 1–2 business days after confirmation by a manager. We deliver throughout Ukraine with Nova Poshta to a branch, parcel locker, or by courier to your address. Delivery cost is calculated at the carrier’s rates upon receipt.
Payment: Pay on delivery · Card transfer · Bank transfer · Crypto wallet · PayPal
MOTS-c is a short peptide of 16 amino acids, associated with the mitochondrial genome. Its discovery changed the traditional view of mitochondria: today they are considered not only as the "power stations" of the cell, but also as part of a complex system of metabolic signal transmission.
That is why MOTS-c is actively studied in the context of metabolism, energy metabolism, physical endurance, muscle work, insulin sensitivity and aging processes.
If a person feels that after 35–40 years it has become more difficult to tolerate stress, recovers longer after training, has become constantly tired or has become more difficult to control weight, the topic of mitochondrial health is naturally of interest.
But it is important to separate promising research directions and proven treatments.
One of the most studied mechanisms of MOTS-c is its interaction with AMPK, a cellular sensor of energy status.
AMPK is involved in the regulation of glucose and fatty acid utilization, energy balance, and cellular adaptation to energy deficiency.
In preclinical studies, MOTS-c has been shown to affect metabolic homeostasis and skeletal muscle metabolism.
This is where the great interest in MOTS-c in the field of metabolic health and physical performance arose.
When we talk about energy, it is not only about coffee, sleep, or the number of calories.
Mitochondria are directly involved in the production of cellular energy, so researchers are interested in the possibility of the influence of mitochondrial peptides on the efficiency of these processes.
In a study published in 2026, MOTS-c administration improved skeletal muscle mitochondrial bioenergetics through mechanisms involving PGC-1α and AMPK. However, this was largely a preclinical study, and the results cannot be directly extrapolated to humans.
This is one of the most interesting areas of MOTS-c research.
In humans, endogenous MOTS-c has been shown to respond to exercise: its levels in skeletal muscle increased after exercise, and its blood concentration temporarily increased during and after exercise.
In animal studies, MOTS-c administration has also been associated with improved exercise capacity and metabolic adaptation in muscles.
Therefore, MOTS-c is currently being actively discussed in the context of endurance, training, muscle function and recovery, although the clinical efficacy of MOTS-c administration in humans has yet to be confirmed.
Another popular topic is MOTS-c and insulin resistance.
In a fundamental work in Cell Metabolism, MOTS-c regulated metabolic homeostasis and insulin sensitivity. In experimental models, it protected mice from age-related and high-fat diet-induced insulin resistance.
These are interesting results, but they do not mean that MOTS-c is already a proven treatment for insulin resistance in humans.
With elevated insulin, glucose or HOMA-IR, first of all, an assessment of the metabolic state and the causes of the disorder is required.
This is the query that people often type into Google.
MOTS-c should not be positioned as a direct analogue of semaglutide, tirzepatide or retatrutide.
It is being studied in a completely different context - mitochondrial function, metabolic homeostasis and energy metabolism.
In animal models, MOTS-c has affected obesity and insulin resistance, but there is currently insufficient evidence to promise similar weight loss in humans.
Therefore, the statement “MOTS-c burns fat” would be too strong.
With age, the body's metabolic and physical adaptations change, so a separate area of research on MOTS-c concerns aging and age-related decline in physical performance.
In a study by Nature Communications, MOTS-c improved physical performance in old mice and affected skeletal muscle metabolism. The authors also found a connection between natural MOTS-c and physical exertion in humans.
Therefore, MOTS-c is often mentioned in the context of healthy aging, but it is still premature to call it a proven "anti-aging peptide."
| Active ingredient | MOTS-c |
|---|---|
| Product form | Pre-filled pen |
| Dosage | 10 mg |
| Volume | 3 ml |
| Route of administration | Subcutaneous injection |
| Requires reconstitution | No |
| Storage conditions | 2–8 °C (refrigerated) |
| Quantity per package | 1 pre-filled pen |
| Country of origin | ОАЕ |
MOTS-c is a mitochondrial peptide that is being studied in the context of energy metabolism, metabolism, muscle function, and healthy aging.
MOTS-c is being studied for its potential effects on mitochondrial function, energy metabolism, metabolic adaptation, endurance, and recovery from exercise.
MOTS-c is associated with cellular energy metabolism and mitochondrial function. However, its use specifically for the treatment of chronic fatigue currently lacks sufficient clinical evidence.
MOTS-c is not a GLP-1 analogue for weight loss. It is being studied in the context of metabolism, insulin sensitivity, and energy metabolism, but there is currently insufficient evidence of weight loss in humans.
In preclinical studies, MOTS-c has been shown to be associated with improvements in glucose metabolism and insulin sensitivity. Clinical data for the use of MOTS-c as a treatment for insulin resistance are not yet sufficient.
MOTS-c is being studied in relation to skeletal muscle function, AMPK, mitochondrial metabolism, and exercise adaptation, which is why it is of interest to athletes looking to improve recovery.
These are different molecules. NAD+ is a coenzyme necessary for many cellular processes, and MOTS-c is a mitochondrial peptide involved in signaling mechanisms regulating metabolism.
Both are associated with mitochondria but have different mechanisms of action. MOTS-c is a mitochondrial signal peptide, while SS-31 is being investigated for its interaction with the inner mitochondrial membrane.
MOTS-c Afira 10 mg / 3 ml is presented in the Nova Vroda catalog. On the product page you can view the current price, specifications and product information.
MOTS-c Afira in the presented format contains 10 mg / 3 ml, 30 mg / 3 ml and is available in a ready-to-use syringe pen.